PORTON DOWN, England -
Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed two patent license agreements with Roche Molecular Systems, Inc. (RMS).
The licenses signed on 15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and melt analysis and will allow Enigma to commercialize HybProbe PCR tests for human and veterinary in vitro diagnostics on a worldwide basis. The two licenses with RMS complement Enigma’s existing patent portfolio as well as intellectual property licensed by Celera Diagnostics for real-time PCR thermal cyclers.
Enigma is currently developing a series of highly multiplexed, HybProbe assays for its infectious disease programs including pandemic and seasonal influenza, chlamydia and MRSA. These tests will be combined with Enigma’s revolutionary fully automated real-time PCR system, the Enigma ML (mini-laboratory), enabling fast and accurate ‘test and treat’ molecular diagnostics at point-of-care.
Financial terms were not disclosed.
About Enigma Diagnostics Limited
Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.
Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma’s commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.
Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licenses from Applied Biosystems and Celera Diagnostics for commercialization of real-time PCR instruments. Enigma’s R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.
For more information visit www.enigmadiagnostics.com
UK Contact: Enigma Diagnostics Deborah Cordingley deborah.cordingley@enigmadiagnostics.com +44-1980-590131 US Contact: Richard Lewis Communications, Inc +1-212-827-0020 Andrew Mielach - Media amielach@rlcinc.com Cecelia Heer - Investors cheer@rlcinc.com
Source: Enigma Diagnostics Limited
UK Contact, Enigma Diagnostics, Deborah Cordingley, +44-1980-590131, deborah.cordingley at enigmadiagnostics.com; or US Contact, Media, Andrew Mielach, amielach at rlcinc.com, or Investors, Cecelia Heer, cheer at rlcinc.com, both of Richard Lewis Communications, Inc., +1-212-827-0020, for Enigma Diagnostics Limited
Related Press Releases
/C O R R E C T I O N -- Enigma Diagnostics Limited/June 29th, 2009 PORTON DOWN, England - In the news release, "Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency" issued on 30 Jun 2009 13:17 GMT, by Enigma Diagnostics Limited over PR Newswire, we are advised by a representative of the company that a second footnote has been added at the end of the fourth paragraph. The note references the following link: enigmadiagnostics.com/template2.php?page=news.php&m=4
Complete, corrected release follows:
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today successful independent testing for bovine viral diarrhoea (BVD) by the Veterinary Laboratories Agency to evaluate the performance of the Enigma FL (Field Laboratory).
Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories AgencyJune 29th, 2009 PORTON DOWN, England -
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today successful independent testing for bovine viral diarrhoea (BVD) by the Veterinary Laboratories Agency to evaluate the performance of the Enigma FL (Field Laboratory). BVD is considered to be one of the main threats to cattle (1), affecting the majority of herds in the UK.
Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent OfficeJune 15th, 2009 PORTON DOWN, England - Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today it was issued European Patent EP1044283, which covers the use of endonuclease-based reporting in PCR and other nucleic acid amplification technologies. Becton, Dickinson and Company (BD) had filed a claim in opposition to this patent which was rejected by the European Patent Office at a proceeding in Munich on May 28.
Sirius Genomics Announces 2009 Board of DirectorsJune 7th, 2009 VANCOUVER - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that it has elected its 2009 Board of Directors at its recent Annual General Meeting. The six-member Board consists of: Dr.
Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic AssaysJune 1st, 2009 SAN RAMON, California - BioGenex, a developer of innovative instruments and reagents for automated slide based staining systems for molecular diagnostics, announced today that Abbott has entered into a definitive agreement to extend the technology co-development and distribution agreement to market the Xmatrx(R) platform for the automation of Abbott's extensive FISH product line. Under the terms of the agreement Abbott customers will have the option to run IHC and ISH on the Xmatrx and BioGenex customers to run FISH on their system.
Agendia Supports Genentech's Citizen's Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory StandardsMay 27th, 2009 HUNTINGTON BEACH, California, and AMSTERDAM - Agendia, a world leader in molecular cancer diagnostics, today announced its strong support of Genentech's Citizen's Petition. Filed on December 5, 2008, Docket No.
Agendia Opens CLIA-Registered U.S. Genomics LaboratoryMay 25th, 2009 HUNTINGTON BEACH, California and AMSTERDAM - Agendia Increases U.S. Footprint with Domestic Executive Team and Operations
Agendia, a world leader in molecular cancer diagnostics, today announced the opening of its U.S.
Copan and POCARED Diagnostics Partner to Enhance the Use of Liquid Based Microbiology and Introduce the Next Generation Microbiology SystemsMay 17th, 2009 BRESCIA, Italy - Alliance Aims to Develop Powerful Tools for Accurate and Rapid Microbiology Testing Leading to Improved Patient Outcomes
Under the partnership, the two companies will enhance the use of liquid based microbiology diagnostic products that incorporate Copan innovative collection and transport devices (like ESwab) for use in combination with POCARED's real-time quantification and identification platform. The Copan and POCARED partnership will also introduce a new level of automation and ease of use.
Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer TestingApril 28th, 2009 SYDNEY - To Receive Milestone Payments from Quest Diagnostics
Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide milestone payments over the next two years to Clinical Genomics to further develop its portfolio of gene-based biomarkers associated with early onset of colorectal cancer. Clinical Genomics was awarded the payments after successfully achieving key research and development goals.
BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery ServicesApril 5th, 2009 BEIJING - BioDuro announced today that they have entered into a strategic partnership with Roche to support discovery phase research efforts at Roche's global research sites. BioDuro will provide research services in the areas of discovery chemistry and biology, which can help to shorten (internal) drug discovery timelines.
Related News
Roche says half-year net income down 29 percent after Genentech takeoverJuly 23rd, 2009 Roche says half-year profit down 29 percentGENEVA — Pharmaceuticals maker Roche Holding AG on Thursday posted a 29 percent drop in six-month net profit because of costs related to the takeover of California-based Genentech. However, sales were strong, helped by the popularity of antiviral Tamiflu in the face of the swine flu pandemic.
Roche says half-year profit down 29 percent with Genentech buy, but boosted by TamifluJuly 23rd, 2009 Roche half-year profit down 29 percentGENEVA — Pharmaceuticals maker Roche Holding AG on Thursday posted a 29 percent drop in six-month net profit because of costs related to the takeover of California-based Genentech. However, sales were strong, helped by the popularity of antiviral Tamiflu in the face of the swine flu pandemic.
Serverside Group granted second patent on core card customization architectureMay 21st, 2009 LONDON - Global technology provider, Serverside Group, announced that the Indian Patent Office has granted a patent directed to its core card customization architecture, thus establishing an international trend. Since the Indian filing was part of an international strategy, the grant of the Indian patent, which follows the grant of a European Patent, not only enhances Serverside's competitive position in India but indicates the likely outcome in other territories yet to come to grant.
Judge rejects plaintiff's lawsuit against cup maker in first-of-its-kind patent caseJuly 8th, 2009 Judge closes door on legal quirk in patent lawALEXANDRIA, Va. — A federal judge has turned away a first-of-its-kind lawsuit filed by an attorney seeking to exploit a quirk in federal patent law that had been dormant for more than a century.
Judge dismisses Guardian Media's patent-infringement claim against NintendoJune 12th, 2009 Judge tosses patent claim against NintendoREDMOND, Wash. — A judge has dismissed a patent-infringement lawsuit against Nintendo over the company's Wii video game machine.
Formula Systems CFO Naamit Salomon leaving to pursue other opportunitiesAugust 26th, 2009 Formula Systems announces departure of CFONEW YORK — Formula Systems (1985) Ltd. said Wednesday that its chief financial officer is leaving to pursue other opportunities.
Continucare says it bought sleep study testing facility operator for an undisclosed amountAugust 13th, 2009 Continucare buys Professional Sleep DiagnosticsMIAMI — Continucare Corp. said Thursday it bought Professional Sleep Diagnostics Inc., a company that operates 13 sleep diagnostic centers, for an undisclosed amount.
Diagnostics product maker Qiagen NV announces offering of new common sharesSeptember 22nd, 2009 Qiagen NV announces offering of new common sharesNetherlands-based diagnostic products maker Qiagen NV announced on Tuesday a placement of 27.5 million newly issued common shares in an international offering. Shares will be offered to institutional investors outside the United States and as a registered offering in the United States, the company said in a statement.
Roche gives poor countries easier access to swine flu drug TamifluJuly 1st, 2009 Roche to ease access to TamifluBASEL, Switzerland — Pharmaceutical maker Roche Holding AG said Wednesday a new initiative will ensure that poor countries get its antiviral drug against swine flu at a lower price. Under the Tamiflu Reserves Program, Roche will produce and ship the drug to developing countries upon order at a "significantly reduced price," it said.
Supreme Court to decide whether to limit 'business method' patentsJune 1st, 2009 Court to decide whether to limit patentsWASHINGTON — The Supreme Court has decided to take on an appeal that could decide whether someone can get a patent for a complex business idea. The high court on Monday decided to hear an appeal from Bernard Bilski and Rand Warsaw, who attempted to patent a method for managing weather-related risk having to do with trading in commodities.
